Markets:

Overview

News

Currencies

International

Treasuries

Pfizer (NY:PFE)

26.62 UNCHANGED

Streaming Delayed Price Updated: 7:00 PM EDT, Aug 11, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Pfizer Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts ↗

August 04, 2026

Pfizer (PFE) will release Q2 earnings on Aug. 4, expected to report lower EPS of 68 cents and revenue at $14.39B. Stock rose 0.1% on Monday.

Via Benzinga

SpaceX Could Swing $204 Billion After Earnings ↗

August 03, 2026

Earnings set for tight window on Tuesday, Benzinga Pro data show options pricing 3.19% move for Pfizer and 5.15% for Amgen and Gilead Sciences.

Via Benzinga

Pfizer's Stock Has Been a Dud Over the Past 5 Years, but Is It Still Worth Buying for Its 6.9% Yield? ↗

August 03, 2026

The stock's yield is more than six times the S&P 500 average.

Via The Motley Fool

Topics Stocks

Pfizer (PFE) Q2 Earnings: What To Expect

August 02, 2026

Global pharmaceutical company Pfizer (NYSE:PFE) will be reporting earnings this Tuesday before market hours. Here’s what to expect. Pfizer beat analysts’ rev...

Via StockStory

Bristol Myers Squibb Isn't Nearly as Cheap as It Looks -- Here's the 1 Thing That Could Change That ↗

August 01, 2026

Bristol Myers Squibb's P/E ratio is below the industry average, but you have to take this key fact into consideration before buying it.

Via The Motley Fool

Topics Intellectual Property

Pfizer Yields 6.8%, Trades at 8.5X Earnings, and Has a Promising Late-Stage Weight Loss Drug. Why Are So Many Investors Still Ignoring the Stock? ↗

July 31, 2026

There is more to this stock than meets the eye.

Via The Motley Fool

Topics Intellectual Property

Regeneron Pharmaceuticals Q2 Earnings Call Highlights ↗

July 30, 2026

Regeneron Pharmaceuticals (NASDAQ:REGN) reported second-quarter revenue growth of 17% from a year earlier to $4.3 billion, supported by continued strength in Dupixent, EYLEA HD and Libtayo. Non-GAAP...

Via MarketBeat

Topics ETFs Earnings

Regency Centers Q2 Earnings Call Highlights ↗

July 30, 2026

Regency Centers (NASDAQ:REG) reported second-quarter operating momentum marked by higher occupancy, rent growth and an expanded development pipeline, prompting the grocery-anchored shopping center...

Via MarketBeat

Topics ETFs Earnings

Pfizer Prepares Global Regulatory Litfulo Filings Following Skin Pigment Improvements In Late-Stage Trials ↗

July 30, 2026

Pfizer reports Phase 3 data for LITFULO in treating nonsegmental vitiligo and plans to submit global regulatory filings.

Via Benzinga

Pfizer Announces Positive Topline Phase 3 Results for LITFULO in Patients with Nonsegmental Vitiligo

July 30, 2026

From Pfizer Inc.

Via Business Wire

What Health Experts Want You to Know About Pneumococcal Pneumonia

July 30, 2026

Via StatePoint Media

European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union

July 29, 2026

From Pfizer Inc.

Via Business Wire

AbbVie Has Raised Its Dividend for 53 Straight Years and Still Looks Attractively Valued. Is This Dividend King the Smartest Buy in Healthcare Right Now? ↗

July 29, 2026

AbbVie still looks like a compelling buy at its all-time high.

Via The Motley Fool

Topics Intellectual Property

Global Oral Contraceptive Drugs Market Growing at 7.3% CAGR Through 2034 ↗

July 29, 2026

According to a new report from Intel Market Research, the global Oral Contraceptive Drugs market was valued at USD 12.9 billion in 2024 and is projected to

Via Talk Markets

GOP Congressman Slams JD Vance's Silence Over CDC's $1.24 Billion Pfizer COVID Vaccine Contracts: 'Why Isn’t He Speaking Out' ↗

July 27, 2026

Rep. Thomas Massie questions JD Vance's silence after the Trump CDC established a $1.24 Billion Pfizer COVID-19 vaccine contract.

Via Benzinga

Topics Government

Generic Pharmaceuticals Stocks Q1 Highlights: Viatris (NASDAQ:VTRS)

July 26, 2026

The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how generic pharmaceutical...

Via StockStory

Topics Artificial Intelligence Intellectual Property

3 Absurdly Cheap Dividend Stocks to Buy Before August ↗

July 26, 2026

Far from "yield traps," these high-yield dividend stocks represent good value at current prices.

Via The Motley Fool

Topics Artificial Intelligence

Pfizer's Dividend Yield Looks Almost Too Good. Here's Why Management Isn't Worried. ↗

July 25, 2026

Pfizer has a 6.8% yield at a time when the market's yield is roughly 1%: Is there something wrong?

Via The Motley Fool

3 Healthcare Stocks We Keep Off Our Radar

July 24, 2026

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Players catalyzing medical advancements have...

Via StockStory

BioNTech's Next Act Has Nothing to Do With COVID. Here's the $500 Billion Market Some Investors Are Ignoring ↗

July 23, 2026

Could it become as successful in this niche as it was in the coronavirus vaccine market?

Via The Motley Fool

Is Pfizer's 7% Dividend Yield Too Good to Be True? Here's the Straight Answer ↗

July 23, 2026

Income seekers shouldn't give up on the stock yet.

Via The Motley Fool

3 Healthcare Stocks with Competitive Advantages

July 23, 2026

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advanceme...

Via StockStory

FDA Grants Priority Review for Pfizer’s TALZENNA Plus XTANDI for the Treatment of Metastatic Prostate Cancer

July 22, 2026

From Pfizer Inc.

Via Business Wire

Want Income for Life? Here Are 3 Stocks to Buy Now and Never Sell. ↗

July 22, 2026

A strong yield and an impressive track record of dividend growth aren't enough. The underlying business needs to be enduring.

Via The Motley Fool

Topics Economy

Pfizer Suspends Popular Menopause Cream in India ↗

July 20, 2026

A Premarin shortage in India leaves menopausal patients facing limited treatment options as Pfizer halts cream distribution.

Via Benzinga

Could Pfizer Ultimately Be the Biggest Winner in the $100 Billion Weight-Loss Market? ↗

July 20, 2026

It is definitely a strong contender.

Via The Motley Fool

Topics Intellectual Property

3 Unpopular Stocks We’re Skeptical Of

July 20, 2026

Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cord...

Via StockStory

1 Stock Under $50 to Target This Week and 2 We Question

July 20, 2026

Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline...

Via StockStory

Looking for Cheap Income Stocks? Why Pfizer Belongs on Your Shortlist Right Now ↗

July 19, 2026

Pfizer is a highly respected drug company facing normal industry headwinds.

Via The Motley Fool

Topics Intellectual Property

Pfizer Paid Out $14.6 Billion in Dividends Over the Last 18 Months. Can It Keep This Up Through the Patent Cliff? ↗

July 18, 2026

Pfizer's dividend yield is 7% for a very good reason: investors are worried about the risk of a dividend cut.

Via The Motley Fool

Topics Intellectual Property

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.